Phendimetrazine API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Phendimetrazine API 634-03-7?
- Description:
- Here you will find a list of producers, manufacturers and traders of Phendimetrazine. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Phendimetrazine
- Synonyms:
- Cas Number:
- 634-03-7
- DrugBank number:
- DB01579
- Unique Ingredient Identifier:
- AB2794W8KV
About Phendimetrazine
So, what does it do? Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.
Not sure if this is the exact product you're looking for? Contact the supplier by using the send inquiry button.
Phendimetrazine is a type of Appetite suppressants
Appetite suppressants are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in managing weight loss and obesity-related conditions. These substances act by modulating the appetite-regulating centers in the brain, leading to reduced food cravings and decreased hunger sensations.
One commonly used appetite suppressant API is phentermine. It works by stimulating the release of norepinephrine, a neurotransmitter that affects appetite control. Phentermine enhances satiety and decreases the appetite, thereby promoting weight loss. Another widely prescribed appetite suppressant is liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It increases feelings of fullness and regulates glucose metabolism.
These APIs are typically formulated into oral medications, such as tablets or capsules, for easy administration. They are often prescribed as part of a comprehensive weight management program that includes a balanced diet and exercise.
Appetite suppressants can be effective tools for individuals struggling with excessive food intake or obesity. However, it's important to note that these medications should be used under the guidance of a healthcare professional. They may have potential side effects and contraindications, which need to be evaluated on an individual basis.
In conclusion, appetite suppressant APIs are valuable pharmaceutical ingredients that help control food cravings and reduce hunger, aiding in weight management. When used responsibly and as part of a holistic approach to health, these medications can contribute to achieving and maintaining a healthy weight.
Phendimetrazine (Appetite suppressants ), classified under Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
